Using genetically engineered mouse models of breast cancer, Blomberg demonstrated that ICB treatment increased interleukin 5 (IL5) secretion by CD4+ T cells, which in turn increased eosinophil production in the bone marrow. This evidence concerns the gene IL5 and breast carcinoma.